Fan Zhang1, Xingyu Feng2, Yong Li2, Juan Yan3, Zhilin Zhang4, Xiao Song4. 1. School of Graduate Studies, Hebei North University, Zhangjiakou, China. 2. Department of General Surgery, Guangdong Provincial People's Hospital, Guangzhou, China. 3. Department of Pharmacy, the First Affiliated Hospital of Hebei North University, Zhangjiakou, China. 4. Department of Radiotherapy, the First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Abstract
Background: Both neoadjuvant chemoradiotherapy (nCRT) and adjuvant chemoradiotherapy (aCRT) have survival advantages over surgery alone in patients with adenocarcinoma of the oesophagogastric junction (AEG). However, whether there is a difference in the survival benefit between these two treatments and who can benefit from them remains controversial, and there are currently no randomised controlled trials to address these issues. This study compared the survival outcomes of patients with locally advanced AEG receiving nCRT and aCRT. Methods: The data of patients with locally advanced AEG were collected from the Surveillance, Epidemiology, and End Results (SEER) database (2004-2015). Patients in the nCRT and aCRT groups were propensity-score matched 1:1, and the Kaplan-Meier method and log-rank test were used for survival analysis between the two groups. Univariable and multivariable Cox regression models were performed to identify the prognostic factors. Results: Of the 1,436 cases diagnosed as locally advanced AEG, we included 442 in the final analysis. The median overall survival (OS) of the nCRT and aCRT cohorts were 30.0 and 25.0 months, respectively (P=0.042), and the median tumour specific survival times were 37.0 and 31.0 months, respectively (P=0.249). Multivariable Cox regression analysis showed that OS was independently related to age [<60 years vs. ≥70 years, hazard ratio (HR) =0.619, 95% CI: 0.510-0.751, P<0.001; 60-69 years vs. ≥70 years, HR =0.661, 95% CI: 0.536-0.814, P<0.001] and N stage (N2 vs. N1, HR =1.213, 95% CI: 1.002-1.468, P=0.048; N3 vs. N1, HR =1.606, 95% CI: 1.190-2.167, P=0.002). Through stratifying patients by TNM stage, stage IIIB, and N1 stage, we observed that patients receiving nCRT had a better prognosis. Conclusions: Patients receiving nCRT had significantly better survival than those receiving aCRT. nCRT may offer some therapeutic benefits in patients with IIIB stage AEG. 2022 Journal of Gastrointestinal Oncology. All rights reserved.
Background: Both neoadjuvant chemoradiotherapy (nCRT) and adjuvant chemoradiotherapy (aCRT) have survival advantages over surgery alone in patients with adenocarcinoma of the oesophagogastric junction (AEG). However, whether there is a difference in the survival benefit between these two treatments and who can benefit from them remains controversial, and there are currently no randomised controlled trials to address these issues. This study compared the survival outcomes of patients with locally advanced AEG receiving nCRT and aCRT. Methods: The data of patients with locally advanced AEG were collected from the Surveillance, Epidemiology, and End Results (SEER) database (2004-2015). Patients in the nCRT and aCRT groups were propensity-score matched 1:1, and the Kaplan-Meier method and log-rank test were used for survival analysis between the two groups. Univariable and multivariable Cox regression models were performed to identify the prognostic factors. Results: Of the 1,436 cases diagnosed as locally advanced AEG, we included 442 in the final analysis. The median overall survival (OS) of the nCRT and aCRT cohorts were 30.0 and 25.0 months, respectively (P=0.042), and the median tumour specific survival times were 37.0 and 31.0 months, respectively (P=0.249). Multivariable Cox regression analysis showed that OS was independently related to age [<60 years vs. ≥70 years, hazard ratio (HR) =0.619, 95% CI: 0.510-0.751, P<0.001; 60-69 years vs. ≥70 years, HR =0.661, 95% CI: 0.536-0.814, P<0.001] and N stage (N2 vs. N1, HR =1.213, 95% CI: 1.002-1.468, P=0.048; N3 vs. N1, HR =1.606, 95% CI: 1.190-2.167, P=0.002). Through stratifying patients by TNM stage, stage IIIB, and N1 stage, we observed that patients receiving nCRT had a better prognosis. Conclusions: Patients receiving nCRT had significantly better survival than those receiving aCRT. nCRT may offer some therapeutic benefits in patients with IIIB stage AEG. 2022 Journal of Gastrointestinal Oncology. All rights reserved.
Entities:
Keywords:
Adenocarcinoma of the oesophagogastric junction (AEG); Surveillance, Epidemiology, and End Results (SEER) database; adjuvant chemoradiotherapy (aCRT); neoadjuvant chemoradiotherapy (nCRT); propensity score matching (PSM) analysis
Authors: H Bleiberg; J C Goffin; O Dalesio; M Buyse; J C Pector; M Gignoux; A Roussel; G Samana; J Michel; A Gerard Journal: Eur J Surg Oncol Date: 1989-12 Impact factor: 4.424
Authors: Vincenzo Valentini; Francesco Cellini; Bruce D Minsky; Gian Carlo Mattiucci; Mario Balducci; Giuseppe D'Agostino; Elisa D'Angelo; Nicola Dinapoli; Nicola Nicolotti; Chiara Valentini; Giuseppe La Torre Journal: Radiother Oncol Date: 2009-07-06 Impact factor: 6.280